BioSpace News Archive

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2019.

Bio-Techne Corporation reported its financial results for the first quarter ended September 30, 2019.

Pfizer Inc. reported financial results for third-quarter 2019 and updated certain components of its 2019 financial guidance..

G1 Therapeutics, Inc., a clinical-stage oncology company, announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2019 on Tuesday, November 5, 2019 at 4:30 p.m. ET..

Sunesis Pharmaceuticals, Inc. announced that it will host a conference call on Tuesday, November 12th, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2019..

Menlo Therapeutics Inc. announced that it has completed enrollment of patients in its two Phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of pruritus associated with prurigo nodularis The U.S. and European Phase 3 trials enrolled 285 and 295 patients, respectively.

NGM Biopharmaceuticals, Inc., a clinical stage biotechnology company focused on developing transformative therapeutics for patients, announced the appointment of Valerie Pierce as Senior Vice President, General Counsel and Chief Compliance Officer.

Proffered paper presentation to highlight new clinical data from a Phase 2a study evaluating BL-8040 in combination with pembrolizumab and chemotherapy in metastatic pancreatic cancer

Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that it will report its third quarter 2019 financial results on Tuesday, November 5, 2019.

Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, announced the completion of a $50 million Series A financing.